Hepatitis C in the pediatric population: Transmission, natural history, treatment and liver transplantation

Table 1 Selected pegylated interferon/ribavirin treatment trials in children with chronic hepatitis C infection n (%)

Ref.	n	Treatment	Sustained virological response
			All types	HCV type 1	HCV type 2/3/6
Wirth et al[26]	41	IFN-2b-ribavirin	25 (61)	18 (53)	7 (100)
González-Peralta et al[25]	118	IFN-2b-ribavirin	54 (46)	33 (36)	21 (84)
Wirth et al[27]	62	PEG-IFN-2b-ribavirin	36 (59)	22 (48)	13 (100)
Wirth et al[28]	107	PEG-IFN-2b-ribavirin	70 (65)	38 (53)	28 (93)
Schwarz et al[29]	55	PEG-IFN-2a-ribavirin	29 (53)	21 (47)	8 (80)
Schwarz et al[29]	59	PEG-IFN-2a	12 (21)	8 (17)	4 (36)

Modified from reference [20]. PEG-IFN: Pegylated interferon; HCV: Hepatitis C virus.

Table 2 Orthotopic liver transplants performed from January 1, 2008 through April 30, 2013 for pediatric patients (age 0-17) with a diagnosis of hepatitis C

	2008	2009	2010	2011	2012	2013	Total
Initial OLT	8	3	6	4	7	4	32
Retransplant	0	1	0	0	1	0	2
Total	8	4	6	4	8	4	34

Based on Organ Procurement and Transplantation Network data. OLT: Orthotopic liver transplant.

Table 3 1, 3, and 5-year graft and patient survival rates for deceased donor liver transplants performed for patients with hepatitis C between January 1, 2002 through April 30, 2007

		1-yr	3-yr	5-yr
		(95%CI)	(95%CI)	(95%CI)
Pediatric
	Graft	73.73%	64.52%	52.23%
		(56.73-90.73)	(46.72-82.31)	(34.45-70.01)
	Patient	87.69%	83.70%	79.05%
		(72.66-100.0)	(66.93-100.0)	(60.34-97.76)
Adult
	Graft	83.29%	71.58%	64.36%
		(82.58-83.99)	(70.72-72.43)	(63.45-65.28)
	Patient	87.29%	76.58%	69.75%
		(86.65-87.93)	(75.76-77.40)	(68.85-70.66)

Based on Organ Procurement and Transplantation Network data.